- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04732260
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1) (CYMEVAL3-STEP1)
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1
In the model of the perfused cotyledon, Letermovir crosses the placenta to reach appropriate fetal concentration. The cotyledon model can only be performed in the third trimester placenta. Although it is probable that the transplacental passage in the second trimester is in the same range than the one found in the 2th trimester, it needs to be confirmed. The study will be divided in 2 steps: step 1 will study the Letermovir transplacental transfer in the second trimester and step 2 will test the efficacy of letermovir to inhibit replication in infected fetuses.
Main objective To measure the Letermovir transplacental transfer in the second trimester and its accumulation in the amniotic fluid and the placenta in the second trimester
Primary end point:
Concentrations reached in fetal blood relative to EC50 of letermovir.
Study Overview
Status
Intervention / Treatment
Detailed Description
The eligible population of step 1 will be pregnant women in their second trimester of pregnancy and undergoing TOP for any fetal abnormality and no evidence of placental dysfunction.
Letermovir (LTM) is a new anti CMV drug, manufactured by Merck that:
- is highly efficient in vitro against CMV (more than ganciclovir the gold standard drug)
- is as efficient as valganciclovir to cure CMV infection and highly efficient as a prophylaxis to avoid CMV infection and disease in bone marrow transplated patients
- is very well tolerated
- has no data from the use in pregnant women and animal studies are insufficient with respect to fetotoxicity, but no specific concern in pregnant women arises from its safety profile
- crosses the placenta in the ex vivo model of the human perfused cotyledon to reach efficient fetal concentration
In this STEP 1 study, we elected to test 2 Letermovir dosages:
- 240 mg given orally once a day. Based on 10% rate of letermovir transplacental passage as demonstrated in the cotyledonon model, we calculated that the dosage of 240 mg given once a day to the pregnant woman should be suffisent to reach efficient concentration in fetal blood.
- 480 mg /day given orally once a day. 480 mg per day is the recommended dose to prevent CMV infection in bone marrow transplanted patients;
The risks added by the study are those of letermovir: nausea, diarrhea and vomiting (frequent), hypersensitivity, loss of appetite, headache, vertigo, abdominal pain, ALT and AST increase, muscule spasm, blood creatinine increase, fatigue, peripheral edema (very rare). The expected benefit for the women is: none.
Women and obstetrician investigator will sign the written consent for the trial.
- Validation of inclusion and non-inclusion criteria will be assessed by the obstetrician investigator as follows:
- age, weight, height and medical history will be collected.
- Inquiry on maternal concomitant treatment(s)
- Blood sampling: (4 ml altogether)
- 1 Heparinate Lithium tube (2 ml) for measurements of urea, creatinine, creatinine clearance, liver enzyme (ALAT ASAT GGT PAL), bilirubine
- 1 EDTA tube of 2 ml for full blood test count These measurements will be done in the biochemistry laboratory of the investigating site.
When validation of inclusion and non-inclusion criteria is done (all the criteria will be available on the day of the baseline visit), the woman receives the tablets of letermovir. They will be allocated either 240 mg or 480 mg up until termination of pregnancy. 5 women will receive 240 mg. In order to have variation in the time elapsed between administration and sampling, it will be asked to 3 women to take the drug every morning and to 2 patients to take the drug every evening. 5 women will receive 480 mg. This time, it will be asked to 2 women to take the drug every morning and to 3 patients to take the drug every evening.
Hence, the day of TOP, patients who take the drug every evening will have the largest delay between the last intake and blood sampling. The patients who take the drug every morning should take the last tablet early in the morning the day of TOP and latest 4 hours before the blood sampling.
After the baseline visit, there will be one other visit just before TOP; the obstetrician investigator will be in charge of this visit:
Maternal examination will comprise:
- Inquiry of potential side effects (nausea, vomiting, diarrhea, rash, cough, peripheral edema, headache, abdominal pain, decrease appetite, others)
- SAE/AE will be collected
- Blood pressure measurement
- Blood sampling: (5 ml) with: one Lithium Heparinate tube for letermovir dosage
- 1 Heparinate Lithium tube (2 ml) for measurements of urea, creatinine, creatinine clearance, liver enzyme (ALAT ASAT GGT PAL), bilirubine
- Hours of the 3 intakes of pills will be recorded in an individual treatment booklet
At TOP, fetal examination will comprise:
- Fetal blood sampling (5 ml in a Lithium Heparinate tube for Letermovir dosage) collected at the time of feticide before lethal injection is given in the umbilical vein under ultrasound guidance.
- Amniotic fluid sampling (5 ml on Lithium heparinate tube for Letermovir dosage) collected by the midwife at the time of artificial rupture of the amniotic membranes.
- Placental biopsies sampling (2 cotyledons for Letermovir dosage) collected after delivery.
- SAE/AE will be collected
- At day 4 after TOP:
Phone call to collect SAE/AE after TOP
The duration of participation of each woman including data collection will be a maximum of 7 days (3 days before the TOP and 4 days after TOP).
The duration of the study will be 9 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hopital Necker - Enfants Malades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant woman ≥ 18 years old
- in her second trimester of pregnancy
- undergoing TOP for any fetal abnormality
- no evidence of placental dysfunction.
- - affiliation to a social security regime//health insurance
- given consent for the study.
- patient must be able and willing to comply with study visits and procedures
Exclusion Criteria:
- Participation to another interventional drug trial (category 1)
- Subject protected by law under guardianship or curatorship
- Woman with creatinine clearance <75 ml/mn/1.73m2
- Woman with liver insufficiency (Child Pugh grade C), AST, ALT 5 x ULN, bilirubin 2 x ULN.
- Woman with known allergy to Letermovir
- Contraindication for the administration of Letermovir listed in the SmPC of Prevymis®
- Woman treated by pimozide, ergot alkaloids, dabigatran, atorvastatin, simvastatin, rosuvastatin, pitavastatine or cyclosporine.
- Concomitant administration of millepertuis
- Woman with hereditary intolerance to galactose, with lactose lapp deficiency, glucose or galactose malabsorption syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: letermovir
Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP
|
Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP. 5 women will receive 240 mg. 5 women will receive 480 mg. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentrations reached in fetal blood relative to EC50 of letermovir.
Time Frame: At termination of pregnancy, on average 3 days after inclusion
|
At termination of pregnancy, on average 3 days after inclusion
|
Collaborators and Investigators
Investigators
- Study Chair: Marianne LERUEZ-VILLE, PhD & MD, Virology laboratory- reference national Lab for CMV infection -Hôpital Necker-Enfants malades, Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP180592
- 2020-002924-35 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnant Women Undergoing TOP
-
King Faisal UniversityCompleted
-
Myant Medical Corp.McMaster UniversityNot yet recruiting
-
Qianfoshan HospitalShandong Nursing AssociationRecruiting
-
Brigham and Women's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingPregnant WomenUnited States
-
Sultan Abdulhamid Han Training and Research Hospital...RecruitingPregnant WomenTurkey
-
Sultan Abdulhamid Han Training and Research Hospital...Not yet recruiting
-
Alexandria UniversityCompleted
-
University of BeykentIstanbul University - Cerrahpasa (IUC)Completed
-
Anhui Provincial HospitalAalto UniversityCompleted
Clinical Trials on Letermovir
-
The First Affiliated Hospital of Soochow UniversityRecruitingHematopoietic Stem Cell Transplantation | CMV InfectionChina
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionUnited States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLCCompletedHIV Infections | Cytomegalovirus | CMVUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
University Medical Centre LjubljanaRecruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCytomegalovirus InfectionFrance
-
Maimónides Biomedical Research Institute of CórdobaMERCK SHARP & DOHME DE ESPAÑA S.A.Not yet recruitingInfections, CytomegalovirusSpain
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCRecruitingCMV | CMV Infection | Hematopoietic Cell TransplantUnited States
-
University of PennsylvaniaMerck Sharp & Dohme LLCNot yet recruitingCytomegalovirus Infections | Transplant-Related DisorderUnited States
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States